Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation

Similar documents
Parathyroid Hormone: An Expert Consultation

Point-of-Care Hemoglobin A1c Testing: OHTAC Recommendation

Arthroscopic Debridement of the Knee: OHTAC Recommendation

Patient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions

1. Develop research question Develop PICOS in consultation with experts, end users, applicant, etc.

Palliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards,

Proposed Strategy for Epilepsy Care in Ontario

Quality-Based Procedures: Clinical Handbook for Primary Hip and Knee Replacement

Clinical Review Report (Sample)

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016

Criteria for Referral to Heart Failure Clinics: A Rapid Review

Action Plans for Individuals with Chronic Obstructive Pulmonary Disease (COPD): A Rapid Review

End-of-Life Care Interventions: An Economic Analysis

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE

Introduction to the POWER Study Chapter 1

MINISTRY OF HEALTH AND LONG-TERM CARE Primary Health Care Team FACT SHEET. New and Enhanced Incentives for Colorectal Cancer Screening

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

Role Description: Regional Colon Cancer Screening/GI Endoscopy Clinical Lead

Outcomes of Peer Supervision across Multiple EBPs within a Community Setting

CSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? What does CQCO do? What is the Cancer System Quality Index?

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

Specialized Multidisciplinary Community-Based Care Series

Quality-Based Procedures: Clinical Handbook for Stroke (Acute and Postacute)

pan-canadian Oncology Drug Review Final Economic Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

Regional Clinical Co-Lead (Physician) Role Opportunity

CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs

Influenza immunization timing

Advocacy Framework. St. Michael s Hospital Academic Family Health Team

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer

pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016

LORRAINE LABBÉ, OCT NOTICE OF HEARING

How to Use the Evidence-Based Practices KITs

COMPUS Vol 2, Issue 8 December 2008

A study about switching from TDF to TAF

Bermuda. Health Council. (2018 Report)

Health and Wellness Alberta Health Care Insurance Plan Statistical Supplement 2006/2007

Clinical Utility of Serologic Testing for Celiac Disease in Asymptomatic Patients

Public Health Unit Tobacco Use Cessation Services

Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot

Hepatitis C treatment program improves access to housing, income and healthcare

Blue Cross Blue Shield of Nebraska Spine Management Provider Training. Provider Training Presented by Leta Genasci

CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

This Frequently Asked Questions document contains various aspects of UIIP in the following sections. Overview Eligibility...

pan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018

Democratic Republic of Congo Country Report FY14

Draft Regulation R-013: Spousal Exemption to Sexual Abuse Provisions and Draft Standard of Practice S-032: Providing Chiropractic Care to a Spouse

Changes to Publicly-Funded Physiotherapy Services

RNAO response to proposed regulation under Smoke-Free Ontario Act, 2017

COMMUNITY RESEARCH WORKSHOP

pan-canadian Oncology Drug Review Final Economic Guidance Report Ibrutinib (Imbruvica) for Mantle Cell Lymphoma July 19, 2016

Tufts Health Plan Overview for Ocean State Immunization Collaborative

Drafting a Coverage Authorization Request Letter

Arthroscopic Debridement of the Knee: An Evidence Update

Harvard Pilgrim Spine Management Provider Training

From Safer Sex Guide. Using condoms

REGIONAL SPECIALIZED GERIATRIC SERVICES GOVERNANCE AUTHORITY. Call for Expressions of Interest from Seniors Advocate/Public Member

The epidemiology of HIV in Canada

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Ontario s Narcotics Strategy

NIA Magellan 1 Medical Specialty Solutions

Ministry of Children and Youth Services. Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW

Detailed results from the START study

Screening Mammography for Women Aged 40 to 49 Years at Average Risk for Breast Cancer

OPIOID PRESCRIBING BY ONTARIO DENTISTS

The Team Approach to Hospice Palliative Care: Integration of Formal and Informal Care at End of Life

ANNEX A PANDEMIC INFLUENZA PLANNING

Diabetes Annual Report. Betsi Cadwaladr University Health Board. January 2015

Family Physicians and Hospital-Based Care: Promoting Continuity and Quality of Care

The Vision. The Objectives

Independent Dental Hygienists under the Non-Insured Health Benefits (NIHB) Program. Questions and Answers

New HIV diagnoses in Ontario: Preliminary update, 2016

Moving towards a National Strategy on Frailty

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

pan-canadian Oncology Drug Review Final Economic Guidance Report Vandetanib (Caprelsa) for Medullary Thyroid Cancer March 30, 2017

Strategic Operational Research Plan February 13, Scientific Office Digestive Health Strategic Clinical Network

Choosing A Doctor. Asking For Help With Your Search. Types Of Primary Care Doctors

RE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT

NEW FOR Children - Vulnerable Adults - Families. E-Learning Child Neglect Managing Allegations Adult investigator training and much much more...

Framework and Action Plan for Autism Spectrum Disorders Services in Saskatchewan. Fall 2008

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

IDU Outreach Project. Program Guidelines

Fiscal Year 2019 (July 1, 2018 June 30, 2019) Membership Information & Application

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018

OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee

July 22, The Smoking Cessation Initiative Description- A Multi-Prong Approach: 1. RNAO Smoking Cessation (SC) Coordinators

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015

Measuring and Mapping the Rheumatology Workforce in Canada An update for: Royal College- National Speciality Societies Human Resource for Health

Information and Data Brief: Venous Leg Ulcers. Find out why a particular quality standard was created and the data behind it

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

Center for Medicaid and CHIP Dental Program Quality, Policy, and Financing Division of Best Practices

Prevention and control of viral hepatitis: Role and impact of liver patient groups in Europe. The Netherlands National hepatitis Centre

CHOOSING WISELY CANADA DE-IMPLEMENTING LOW VALUE CARE

Doravirine vs. darunavir

Transcription:

Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation B McCurdy June 2013 Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11.

Suggested Citation This report should be cited as follows: McCurdy B. Aspartate aminotransferase testing in community-based laboratories: an expert consultation. Toronto, ON: Health Quality Ontario; 2013 June. 11 p. Available from:http://www.hqontario.ca/evidence/publications-andohtac-recommendations/expert-consultations. Conflict of Interest Statement All reports prepared by the Division of Evidence Development and Standards at Health Quality Ontario are impartial. There are no competing interests or conflicts of interest to declare. Disclaimer This report is the work of the Division of Evidence Development and Standards at Health Quality Ontario, and is developed from expert consultation. Expert consultations are used for interventions for which there is very limited evidence, but consensus by experts on the appropriate use. Health Quality Ontario assumes no responsibility for omissions or incomplete analysis resulting from expert consultations. In addition, it is possible that other relevant scientific findings may have been reported since completion of the report. This report is current to the date of publication, and may be superseded by an updated publication on the same topic. Please check the Health Quality Ontario website for a list of all publications: http://www.hqontario.ca/evidence/publications-and-ohtacrecommendations. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 2

About Health Quality Ontario Health Quality Ontario is an arms-length agency of the Ontario government. It is a partner and leader in transforming Ontario s health care system so that it can deliver a better experience of care, better outcomes for Ontarians, and better value for money. Health Quality Ontario strives to promote health care that is supported by the best available scientific evidence. Health Quality Ontario works with clinical experts, scientific collaborators, and field evaluation partners to develop and publish research that evaluates the effectiveness and cost-effectiveness of health technologies and services in Ontario. Based on the research conducted by Health Quality Ontario and its partners, the Ontario Health Technology Advisory Committee (OHTAC) a standing advisory subcommittee of the Health Quality Ontario Board makes recommendations about the uptake, diffusion, distribution, or removal of health interventions to Ontario s Ministry of Health and Long-Term Care, clinicians, health system leaders, and policy makers. Rapid reviews, evidence-based analyses and their corresponding OHTAC recommendations, and other associated reports are published on the Health Quality Ontario website. Visit http://www.hqontario.ca for more information. About Health Quality Ontario Publications To conduct its rapid reviews, Health Quality Ontario and/or its research partners reviews the available scientific literature, making every effort to consider all relevant national and international research; collaborates with partners across relevant government branches; consults with clinical and other external experts and developers of new health technologies; and solicits any necessary supplemental information. In addition, Health Quality Ontario collects and analyzes information about how a health intervention fits within current practice and existing treatment alternatives. Details about the diffusion of the intervention into current health care practices in Ontario can add an important dimension to the review. Information concerning the health benefits, economic and human resources, and ethical, regulatory, social, and legal issues relating to the intervention may be included to assist in making timely and relevant decisions to optimize patient outcomes. Permission Requests All inquiries regarding permission to reproduce any content in Health Quality Ontario reports should be directed to: EvidenceInfo@hqontario.ca. How to Obtain Reports From Health Quality Ontario All rapid reviews are freely available in PDF format at the following URL: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 3

Table of Contents Background... 5 Objective of Analysis... 5 Clinical Need and Target Population... 5 Ontario Context... 5 Expert Consultation... 8 Research Question... 8 Research Methods... 8 Expert Opinion... 8 Findings... 8 Conclusions... 9 Acknowledgements... 10 Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 4

Background Overuse, underuse, and misuse of interventions are important concerns in health care and lead to individuals receiving unnecessary or inappropriate care. In April 2012, under the guidance of the Ontario Health Technology Advisory Committee s Appropriateness Working Group, Health Quality Ontario (HQO) launched its Appropriateness Initiative. The objective of this initiative is to develop a systematic framework for the ongoing identification, prioritization, and assessment of health interventions in Ontario for which there is possible misuse, overuse, or underuse. For more information on HQO s Appropriateness Initiative, visit our website at www.hqontario.ca. Objective of Analysis The objective of this analysis is to determine the clinical utility of aspartate aminotransferase (AST) testing in community-based laboratories. Clinical Need and Target Population Aspartate aminotransferase is an enzyme found in a number of organs and tissues in the body, including the liver, heart, and muscle cells. AST can be measured in the blood stream when one of these organs or tissues is damaged. AST is often used to diagnose or monitor liver damage; however, since it is present in a number of other tissues, it is a relatively non-specific test. There are a number of other liver function tests. One of these tests, alanine aminotransferase (ALT), is more specific than AST. Ontario Context As shown in Figure 1, between the 2005/2006 and 2010/2011 fiscal years, the number of AST tests performed in Ontario community laboratories dropped substantially from 4,711,135 to 2,155,220. This was likely caused by the fact that, in August 2007, AST was replaced on the Ontario laboratory requisition form by ALT.. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 5

Number of AST and ALT tests Figure 1: Aspartate Aminotransferase Tests in Ontario Community Laboratories by Fiscal Year 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 - AST ALT 2005 2006 2007 2008 2009 2010 2011 Fiscal Year Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase Data are based on health care provider claims (excluding out-of-province, out-of-country, and Work Place Safety and Insurance Board claims) in community labs using the Ontario Laboratory Schedule of Benefits fee code L222A (AST) and L223A (ALT). Fiscal service year was defined as having a service date between ccyy-04-01 and ccyy-03-31, assessed to ccyy-09-30 (M7). For example fiscal service year was defined as having a service date between 2003-04-01 and 2004-03-31, assessed to 2004-09-30. The exception is fiscal service year 2011. It is assessed to 2012-06-30 (M4). Data for fiscal year 2011/2012 may not be complete. In fiscal year 2011/2012, the top 5 medical specialties that ordered AST tests in community laboratories were: Family and general practice(69%) Internal medicine(10.1%) Rheumatology(5.8%) Gastroenterology(2.8%) Nurse practitioners(2.5%) In fiscal year 2011/2012 patients received an average of 1.52 tests (range, 1 71). The breakdown of the amount of repeat testing occurring during this time period is shown in Figure 2. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 6

% of patients Figure 2: Frequency of Repeat Aspartate Aminotransferase Testing Conducted in Ontario Community Laboratories in Fiscal Year 2011/2012 80% 74.86% 70% 60% 50% 40% 30% 20% 10% 0% 15.00% 4.87% 2.15% 3.11% 1 2 3 4 5 plus Number of AST tests received by patients in FY 2011/2012 Data are based on Health care provider claims (excluding out-of-province, out-of-country, and Work Place Safety and Insurance Board claims) in community labs using the Ontario Laboratory Schedule of Benefits fee code L222A (AST) and L223A (ALT). Fiscal service year was defined as having a service date between ccyy-04-01 and ccyy-03-31, assessed to ccyy-09-30 (M7). For example fiscal service year was defined as having a service date between 2003-04-01 and 2004-03-31, assessed to 2004-09-30. The exception is fiscal service year 2011, it is assessed to 2012-06-30 (M4). Data for fiscal year 2011/2012 may not be complete. Ontario registered physicians specialties are allocated based on the physician billing pattern for the applicable fiscal service year. For other health care providers, the practicing specialty allocated to the claim submission number as of the last day of each fiscal year was used.. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 7

Expert Consultation Research Question What is the clinical utility of AST testing in community-based laboratories? Research Methods Expert Opinion In August 2012, experts were identified to provide advice on the appropriate use of AST testing in the Ontario health care setting. However, the statements, conclusions, and views expressed in this report do not necessarily represent the views of all experts. Findings Several Ontario experts were consulted, including family physicians, a hepatologist, and a hematologist. The experts agreed that the AST/ALT ratio can, in some cases, provide important information to help differentiate between types of liver damage, in particular when determining if the damage is alcohol related. However, the experts felt that ALT, the more specific liver test, should be the primary test used in community-based laboratories with access through hospitals to those specialists who require the additional information that AST may provide. Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. 8

Conclusions Based on the Ontario utilization data and expert consultations, there is inappropriate AST testing occurring in community laboratories in Ontario. Given the lack of specificity of AST compared to ALT, AST tests have limited utility in the community setting and testing should be restricted. Aspartate Aminotransferase (AST) Testing in Community-Based Laboratories. June 2013; pp. 1 11. 9

Acknowledgements Editorial Staff Pierre Lachaine Aspartate Aminotransferase (AST) Testing in Community-Based Laboratories. June 2013; pp. 1 11. 10

Health Quality Ontario 130 Bloor Street West, 10 th Floor Toronto, Ontario M5S 1N5 Tel: 416-323-6868 Toll Free: 1-866-623-6868 Fax: 416-323-9261 Email: EvidenceInfo@hqontario.ca www.hqontario.ca Queen s Printer for Ontario, 2013 Aspartate Aminotransferase (AST) Testing in Community-Based Laboratories. June 2013; pp. 1 11. 11